Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$653M |
| 2 |
Amazon
AMZN
|
+$602M |
| 3 |
ExxonMobil
XOM
|
+$473M |
| 4 |
Tesla
TSLA
|
+$437M |
| 5 |
Starbucks
SBUX
|
+$380M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Berkshire Hathaway Class A
BRK.A
|
+$511M |
| 2 |
Netflix
NFLX
|
+$427M |
| 3 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$397M |
| 4 |
Nike
NKE
|
+$373M |
| 5 |
Microsoft
MSFT
|
+$365M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.68% |
| 2 | Healthcare | 17.69% |
| 3 | Consumer Discretionary | 13.09% |
| 4 | Industrials | 7.96% |
| 5 | Consumer Staples | 7.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
VOXR
3101
Vox Royalty Corp
VOXR
$368M
| $221K | ﹤0.01% |
107,067
+51,667
| +93% | +$105K |
|
|
EXPR
3102
DELISTED
Express, Inc.
EXPR
| $221K | ﹤0.01% |
26,385
-4,300
| -14% | -$37.8K |
|
3103
2x Long VIX Futures ETF
UVIX
$202M
| $220K | ﹤0.01% |
+80
| New | +$406K |
|
|
FRLN
3104
DELISTED
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
| $220K | ﹤0.01% |
34,460
+8,100
| +31% | +$43.4K |
|
3105
Mineralys Therapeutics
MLYS
$2.25B
| $219K | ﹤0.01% |
25,500
-70,190
| -73% | -$551K |
|
3106
NN Inc
NNBR
$319M
| $219K | ﹤0.01% |
54,800
+17,300
| +46% | +$41.1K |
|
|
TMQ
3107
Trilogy Metals
TMQ
$655M
| $219K | ﹤0.01% |
508,526
+257,026
| +102% | +$115K |
|
3108
Pulmatrix
PULM
$5.73M
| $218K | ﹤0.01% |
117,321
+6,056
| +5% | +$11.6K |
|
|
RTC
3109
DELISTED
Baijiayun Group
RTC
| $216K | ﹤0.01% |
21,579
-1,760
| -8% | -$23.2K |
|
3110
Cocrystal Pharma
COCP
$15.2M
| $215K | ﹤0.01% |
125,128
-1,100
| -0.9% | -$1.96K |
|
3111
JPMorgan BetaBuilders US Aggregate Bond ETF
BBAG
$996M
| $214K | ﹤0.01% |
+4,600
| New | +$206K |
|
3112
P3 Health Partners
PIII
$36.9M
| $214K | ﹤0.01% |
3,040
-4,216
| -58% | -$291K |
|
3113
ProKidney
PROK
$277M
| $214K | ﹤0.01% |
+120,000
| New | +$257K |
|
3114
Protara Therapeutics
TARA
$231M
| $212K | ﹤0.01% |
113,300
+53,200
| +89% | +$78.4K |
|
|
LGO
3115
Largo
LGO
$74.1M
| $211K | ﹤0.01% |
+91,400
| New | +$214K |
|
3116
Beyond Air
XAIR
$5.8M
| $211K | ﹤0.01% |
269
+115
| +75% | +$89.5K |
|
3117
Simply Good Foods
SMPL
$999M
| $210K | ﹤0.01% |
5,300
-800
| -13% | -$29.9K |
|
|
SYBX
3118
DELISTED
Synlogic
SYBX
| $210K | ﹤0.01% |
+54,630
| New | +$138K |
|
3119
Celularity
CELU
$20M
| $209K | ﹤0.01% |
84,347
+30,007
| +55% | +$65.2K |
|
|
CASI
3120
DELISTED
CASI Pharmaceuticals
CASI
| $208K | ﹤0.01% |
29,100
+11,300
| +63% | +$54.4K |
|
|
VINC
3121
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
| $208K | ﹤0.01% |
8,801
+2,156
| +32% | +$36.2K |
|
3122
Marker Therapeutics
MRKR
$19.2M
| $207K | ﹤0.01% |
37,550
-2,700
| -7% | -$9.15K |
|
3123
Repay Holdings
RPAY
$306M
| $205K | ﹤0.01% |
23,951
-111,049
| -82% | -$783K |
|
3124
Harte-Hanks
HHS
$32.4M
| $204K | ﹤0.01% |
30,100
-8,200
| -21% | -$54.7K |
|
|
GHSI
3125
DELISTED
Guardion Health Sciences, Inc. Common Stock
GHSI
| $203K | ﹤0.01% |
38,020
-1,700
| -4% | -$10.3K |
|
Similar funds
Jim Simons's Q4 2023 Portfolio in Review
As of Q4 2023, Jim Simons held 4,318 positions worth $64.6B, up 10% from $58.7B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Jim Simons's Q4 2023 filing shows 702 new, 1,590 increased, 1,355 reduced and 633 closed positions. Its largest new stake was Amazon: 4,296,466 shares worth $653M. The largest sale was Berkshire Hathaway Class A, an estimated $511M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 19% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Jim Simons's largest Q4 2023 buy was Amazon: 4,296,466 shares worth $653M.
- Jim Simons added most to Meta Platforms (Facebook) in Q4 2023, an estimated $653M increase.
- Jim Simons's biggest Q4 2023 reduction was Berkshire Hathaway Class A, cutting an estimated $511M.
- Jim Simons fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2023, selling an estimated $397M.
- Jim Simons's ten largest holdings make up 12% of its $64.6B portfolio in Q4 2023.
- Jim Simons opened 702 new positions and closed 633 in Q4 2023.
- Jim Simons's portfolio value rose 10% quarter-over-quarter to $64.6B.
Based on Renaissance Technologies's 13F filing for Q4 2023, filed 13 Feb 2024.